InduPro Therapeutics has entered into a global strategic collaboration and licensing agreement with US compatriot Eli Lilly potentially valued at approximately USD 950 million, including an upfront payment and equity investment. The partnership will utilise InduPro's proprietary proximity-guided platform to discover and develop novel bispecific (BsAb) and multispecific antibody (MsAb) therapies for oncology.

The agreement focuses on up to three targets, with InduPro leading early discovery efforts. The company's platform, which includes its AI/ML-enabled Membrane Interactomics (MInt) platform, identifies disease-specific co-target pairs by leveraging tumour-associated proximal antigens (TAPAs). This approach aims to develop next-generation therapeutics with improved tumour selectivity, safety and potency, including bispecific antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). The collaboration underscores a shared commitment to advancing spatially informed cancer treatments.

PharmCube's NextBiopharm® database shows that the collaboration comes only one month after InduPro partnered with Sanofi to advance an immunology bispecific for an undisclosed amount. Click here to request a free trial for NextBiopharm®.